80 related articles for article (PubMed ID: 12681268)
1. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
Littlejohns P; Barnett D; Longson C;
Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
[TBL] [Abstract][Full Text] [Related]
2. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
Charlton V
Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
[TBL] [Abstract][Full Text] [Related]
3. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
Charlton V
Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
[TBL] [Abstract][Full Text] [Related]
4. Audit of data redaction practices in NICE technology appraisals from 1999 to 2019.
Osipenko L
BMJ Open; 2021 Oct; 11(10):e051812. PubMed ID: 34615680
[TBL] [Abstract][Full Text] [Related]
5. An empirical ethics study of the coherence of NICE technology appraisal policy and its implications for moral justification.
Charlton V; DiStefano M
BMC Med Ethics; 2024 Mar; 25(1):28. PubMed ID: 38448909
[TBL] [Abstract][Full Text] [Related]
6. Innovation as a value in healthcare priority-setting: the UK experience.
Charlton V; Rid A
Soc Justice Res; 2019; 32(2):208-238. PubMed ID: 31281204
[TBL] [Abstract][Full Text] [Related]
7. The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual.
Angelis A; Harker M; Cairns J; Seo MK; Legood R; Miners A; Wiseman V; Chalkidou K; Grieve R; Briggs A
Value Health; 2023 Oct; 26(10):1503-1509. PubMed ID: 37268059
[TBL] [Abstract][Full Text] [Related]
8. The NHS: assessing new technologies, NICE and value for money.
Stevens A; Chalkidou K; Littlejohns P
Clin Med (Lond); 2011 Jun; 11(3):247-50. PubMed ID: 21902077
[TBL] [Abstract][Full Text] [Related]
9. Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries.
Corbacho B; Drummond M; Santos R; Jones E; Borràs JM; Mestre-Ferrandiz J; Espín J; Henry N; Prat A
Eur J Health Econ; 2020 Jun; 21(4):621-634. PubMed ID: 32026155
[TBL] [Abstract][Full Text] [Related]
10. Impact of NIHR HTA Programme funded research on NICE clinical guidelines: a retrospective cohort.
Turner S; Bhurke S; Cook A
Health Res Policy Syst; 2015 Aug; 13():37. PubMed ID: 26297470
[TBL] [Abstract][Full Text] [Related]
11. Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis.
Hale G; Morris J; Barker-Yip J
J Comp Eff Res; 2023 Nov; 12(11):e230093. PubMed ID: 37724717
[No Abstract] [Full Text] [Related]
12. Appraisal of Novel Oncological Therapies by the Scottish Medicines Consortium and the National Institute for Health and Care Excellence: A Comparative Study of Six Years of Data.
Taylor R
Cureus; 2023 Dec; 15(12):e50560. PubMed ID: 38222244
[TBL] [Abstract][Full Text] [Related]
13. Problems with NICE's severity weights.
Hausman DM
Soc Sci Med; 2024 May; 348():116833. PubMed ID: 38636210
[TBL] [Abstract][Full Text] [Related]
14. How long has NICE taken to produce Technology Appraisal guidance? A retrospective study to estimate predictors of time to guidance.
Casson SG; Ruiz FJ; Miners A
BMJ Open; 2013 Jan; 3(1):. PubMed ID: 23315516
[TBL] [Abstract][Full Text] [Related]
15. What's happening at NICE?
Rawlins MD; Dillon A; Leng G
Clin Med (Lond); 2013 Feb; 13(1):13-5. PubMed ID: 23472486
[TBL] [Abstract][Full Text] [Related]
16. Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals.
Rose M; Rice S; Craig D
Pharmacoecon Open; 2018 Jun; 2(2):97-107. PubMed ID: 29623616
[TBL] [Abstract][Full Text] [Related]
17. Evidence synthesis for decision making 1: introduction.
Dias S; Welton NJ; Sutton AJ; Ades AE
Med Decis Making; 2013 Jul; 33(5):597-606. PubMed ID: 23804506
[TBL] [Abstract][Full Text] [Related]
18. Inequality of access to advanced therapies for patients with inflammatory arthritis: a postcode lottery?
Kaul A; Mistry J; Iagnocco A; Baraliakos X; Bosworth A; McNicol I
Rheumatol Adv Pract; 2021; 5(3):rkab081. PubMed ID: 34859176
[TBL] [Abstract][Full Text] [Related]
19. Redaction at the heart of NICE appraisals.
Cave JA
Drug Ther Bull; 2023 Sep; 61(9):130. PubMed ID: 37524407
[No Abstract] [Full Text] [Related]
20. Treatment Effect Waning Assumptions: A Review of National Institute of Health and Care Excellence Technology Appraisals.
Trigg LA; Melendez-Torres GJ; Abdelsabour A; Lee D
Value Health; 2024 Apr; ():. PubMed ID: 38679289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
